Literature DB >> 30483882

Update on opsoclonus-myoclonus syndrome in adults.

Sun-Young Oh1,2, Ji-Soo Kim3,4, Marianne Dieterich5,6,7.   

Abstract

Opsoclonus-myoclonus syndrome in adults is a rare and heterogeneous disorder with the clinical features of opsoclonus, myoclonus, ataxia, and behavioral and sleep disturbances. The pathophysiology is thought to be immunological on the basis of paraneoplastic or infectious etiologies. Immunomodulatory therapies should be performed although the response may be incomplete. A number of autoantibodies have been identified against a variety of antigens, but no diagnostic immunological marker has yet been identified. This review focuses on underlying mechanisms of opsoclonus-myoclonus syndrome, including findings that have been identified recently, and provides an update on the clinical features and treatments of this condition.

Entities:  

Keywords:  Antibodies; Autoimmune; Encephalitis; Opsoclonus–myoclonus syndrome; Paraneoplastic

Mesh:

Year:  2018        PMID: 30483882     DOI: 10.1007/s00415-018-9138-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  80 in total

1.  Opsoclonus-myoclonus in children associated or not with neuroblastoma.

Authors:  Pauline Krug; Gudrun Schleiermacher; Jean Michon; Dominique Valteau-Couanet; Hervé Brisse; Michel Peuchmaur; Sabine Sarnacki; Hélène Martelli; Isabelle Desguerre; Marc Tardieu
Journal:  Eur J Paediatr Neurol       Date:  2010-01-27       Impact factor: 3.140

2.  Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.

Authors:  Thaís Armangué; Lidia Sabater; Estefanía Torres-Vega; Eugenia Martínez-Hernández; Helena Ariño; Mar Petit-Pedrol; Jesús Planagumà; Luis Bataller; Josep Dalmau; Francesc Graus
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

3.  Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

Authors:  F A Luque; H M Furneaux; R Ferziger; M K Rosenblum; S H Wray; S C Schold; M J Glantz; K A Jaeckle; H Biran; M Lesser
Journal:  Ann Neurol       Date:  1991-03       Impact factor: 10.422

4.  Autoantigen diversity in the opsoclonus-myoclonus syndrome.

Authors:  Luis Bataller; Myrna R Rosenfeld; Francesc Graus; Juan J Vilchez; Nai-Kong V Cheung; Josep Dalmau
Journal:  Ann Neurol       Date:  2003-03       Impact factor: 10.422

5.  Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.

Authors:  Elizabeth D Tate; Tyler J Allison; Michael R Pranzatelli; Steven J Verhulst
Journal:  J Pediatr Oncol Nurs       Date:  2005 Jan-Feb       Impact factor: 1.636

6.  Progressive encephalomyelitis with rigidity.

Authors:  A M Whiteley; M Swash; H Urich
Journal:  Brain       Date:  1976-03       Impact factor: 13.501

Review 7.  Opsoclonus in adults. Report of three cases and review of the literature.

Authors:  K B Digre
Journal:  Arch Neurol       Date:  1986-11

8.  A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom.

Authors:  K Ki Pang; Carlos de Sousa; Bethan Lang; Michael G Pike
Journal:  Eur J Paediatr Neurol       Date:  2009-05-06       Impact factor: 3.140

9.  The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review.

Authors:  Alexis B Rothenberg; Walter E Berdon; Giulio J D'Angio; Darrell J Yamashiro; Robert A Cowles
Journal:  Pediatr Radiol       Date:  2009-05-09

10.  Whole-body tremulousness: isolated generalized polymyoclonus.

Authors:  Andrew McKeon; Sean J Pittock; Graham A Glass; Keith A Josephs; James H Bower; Vanda A Lennon; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2007-09
View more
  25 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Paraneoplastic neurological syndrome: growing spectrum and relevance.

Authors:  Valakunja Harikrishna Ganaraja; Mohamed Rezk; Divyanshu Dubey
Journal:  Neurol Sci       Date:  2022-04-23       Impact factor: 3.307

3.  An unusual occurrence of opsoclonus and liver enzymes elevation in a patient with acute motor and sensory axonal neuropathy subtype of Guillain-Barré syndrome.

Authors:  Hasan Alzuhaily; Eman Khashaneh; Sanaa Albkhetan; Fatima Abbas
Journal:  BMC Neurol       Date:  2022-03-18       Impact factor: 2.474

Review 4.  Eye Movement Disorders in Movement Disorders.

Authors:  Panagiotis Kassavetis; Diego Kaski; Tim Anderson; Mark Hallett
Journal:  Mov Disord Clin Pract       Date:  2022-02-16

Review 5.  Paraneoplastic syndrome in neuroophthalmology.

Authors:  Longdan Kang; Chao Wan
Journal:  J Neurol       Date:  2022-07-02       Impact factor: 6.682

6.  Opsoclonus myoclonus ataxia syndrome following COVID-19 infection.

Authors:  Ismail Ibrahim Ismail; Walaa A Kamel; Ayman Kilany
Journal:  Acta Neurol Belg       Date:  2022-07-14       Impact factor: 2.471

7.  Opsoclonus and Neuroborreliosis: Can't See the Forest for the Trees.

Authors:  Marie Sauvant; Quentin Thomas; Sophie Mohr; Christelle Blanc-Labarre; Yannick Béjot; Benoit Delpont
Journal:  Neurol Clin Pract       Date:  2021-02

Review 8.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

9.  Opsoclonus Following Downbeat Nystagmus in Absence of Visual Fixation in Multiple System Atrophy: Modulation and Mechanisms.

Authors:  Ju-Young Lee; Eunjin Kwon; Hyo-Jung Kim; Jeong-Yoon Choi; Hui Jong Oh; Ji-Soo Kim
Journal:  Cerebellum       Date:  2021-10       Impact factor: 3.847

Review 10.  Paraneoplastic neurological syndrome: an evolving story.

Authors:  Jiraporn Jitprapaikulsan; Pritikanta Paul; Smathorn Thakolwiboon; Shivam Om Mittal; Sean J Pittock; Divyanshu Dubey
Journal:  Neurooncol Pract       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.